Q2 Solutions brings more than 20 years of experience in bioanalytical services, developing robust methods to support all stages of drug discovery and development. We have developed and validated assays for a range of applications, including ADME screening/ADME testing, discovery and development metabolite identification, drug metabolism and pharmacokinetics, immunogenicity testing, biomarker analysis and characterization, and biosimilars testing. Methodologies include LC/MS bioanalysis, LC/MS/MS analysis, hybrid LC/MS assays, and immunoassay and MS-based biomarker assays. Prior to validation, each assay undergoes a formal pre-qualification process in which Q2 Solutions scientists review preliminary data and assess modifications necessary to support validation.
The link below provides a list of validated bioanalytical methods developed by Q2 Solutions to support clinical trial applications, including COVID-19 trials. In addition to listed assays, Q2 Solutions develops customized methods to meet specific challenges.
There is an increase in the complexity of drug modalities along with the need for more sensitive methods. Immunoassays, while often chosen as the first platform to utilize for assessing...
Translational research programs have been created to provide a better understanding of disease susceptibilities and pathway mechanisms. These programs require integration and analysis of multiple...
Learn more about Merck’s Biospecimen and Biorepository Management System (BBMS) - a transformational informatics project that improves operational visibility, increases efficiency, and maintains...